CRISPR/Cas9 gene-corrected hematopoietic stem cell therapy (CRISPR Therapeutics)

N/A

Report date: 2025/03/19 08:59:14

Base Information

Drug NameCRISPR/Cas9 gene-corrected hematopoietic stem cell therapy (CRISPR Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionAlpha-L-iduronidase stimulants
TargetsAlpha-L-iduronidase
Therapy Area/Indications +[1]  N/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics Ag
Inactive CompaniesN/A
Active Indications +[1]  N/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A